PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17364060-3 2006 Combination of IFN preparation with some nucleosides, including ribavirin, proved to be highly effective towards drug-resistant herpes virus. Nucleosides 41-52 interferon alpha 1 Homo sapiens 15-18 20412327-1 2010 AIM: Nucleoside analog (NA)-interferon (IFN) sequential therapy may enable the long-term control of chronic hepatitis B (CHB) and the withdrawal of the nucleoside analog. Nucleosides 5-15 interferon alpha 1 Homo sapiens 40-43 20412327-1 2010 AIM: Nucleoside analog (NA)-interferon (IFN) sequential therapy may enable the long-term control of chronic hepatitis B (CHB) and the withdrawal of the nucleoside analog. Nucleosides 152-162 interferon alpha 1 Homo sapiens 40-43 17958644-3 2007 Better results have recently been reported with pegylated IFN both in IFN-naive and in previous nonresponders to standard IFN, suggesting the use of pegylated IFN as a first-line therapy in chronic hepatitis D. Nucleoside analogues that inhibit hepatitis B virus (HBV) are ineffective against HDV and combination therapy with lamivudine or ribavirin has not shown significant advantages over monotherapy with either standard or pegylated IFN. Nucleosides 211-221 interferon alpha 1 Homo sapiens 58-61 22114715-1 2011 The nucleoside analogue Ribavirin significantly increases patient response to IFN-alpha treatment of HCV, by directly inhibiting viral replication. Nucleosides 4-14 interferon alpha 1 Homo sapiens 78-87 18045284-1 2007 BACKGROUND: Interferon (IFN)-alpha and lamivudine (LAM), a nucleoside analog, are frequently used drugs for the treatment of chronic hepatitis B (CHB), and their combined therapy has been shown to be effective. Nucleosides 59-69 interferon alpha 1 Homo sapiens 12-34 16775956-1 2006 The combination therapy regimen of interferon (IFN)-alpha and lamivudine (LAM), a nucleoside analogue, is lately in use in chronic hepatitis B (CHB) infections. Nucleosides 82-92 interferon alpha 1 Homo sapiens 35-57 29142236-10 2017 The model should help to forecast the outcome of IFN-alpha treatment prior to therapy decision involving nucleoside analogs or IFNs. Nucleosides 105-115 interferon alpha 1 Homo sapiens 49-58 15324946-6 2004 With the introduction of new nucleoside/nucleotide analogs such as entacavir, clevudine, LFd4C,tenofovir, and immunomodulatory agents such as pegylated IFN, new treatment options, either alone or in combination, are being investigated to increase the response rate in treatment-naive and treatment-experienced chronic hepatitis B patients. Nucleosides 29-39 interferon alpha 1 Homo sapiens 152-155 8724854-2 1995 IFN-alpha treatment influenced the metabolism of exogenously supplied nucleobases and nucleosides in a manner expected to contribute to synergistic activity. Nucleosides 86-97 interferon alpha 1 Homo sapiens 0-9 8724854-5 1995 The effects of IFN-alpha on nucleobase/nucleoside metabolism could contribute to synergistic antiviral activity by reducing the accumulation of thymidine/thymine metabolites and decreasing the guanine taken into cells. Nucleosides 39-49 interferon alpha 1 Homo sapiens 15-24 12825459-1 2001 Ribavirin, a nucleoside analog, used in combination with interferon-alpha (IFN alpha) results in a substantial improvement in the sustained virologic response in chronic hepatitis C. Identified antiviral mechanisms of action for ribavirin include: (i) inhibition of viral encoded polymerases; (ii) inhibition of genomic RNA capping; and (iii) inhibition of cellular encoded enzymes that control de novo synthesis of purine nucleosides. Nucleosides 423-434 interferon alpha 1 Homo sapiens 75-84 7627962-9 1995 A comparable antitumor effect was also found when a related nucleoside analogue, 5-propynyloxy-2"-deoxyuridine, was used with FUra+IFN, and it also showed modulating activity when used with only FUra. Nucleosides 60-70 interferon alpha 1 Homo sapiens 131-134 2393279-2 1990 The mechanisms responsible for this synergistic activity are not known, but we hypothesize that IFN-alpha-induced alterations of nucleoside metabolism in virus-infected cells may play an important role. Nucleosides 129-139 interferon alpha 1 Homo sapiens 96-105 2393279-7 1990 Although IFN-alpha affected the metabolism of natural nucleosides in HSV-1-infected cells, it did not significantly reduce the uptake of the antiviral guanosine analog acyclovir into HSV-1-infected cells or the amount of acyclovir-5"-triphosphate accumulated. Nucleosides 54-65 interferon alpha 1 Homo sapiens 9-18 2393279-8 1990 Therefore, in IFN-alpha-treated cells the concentration of a natural nucleoside, thymidine, was reduced, as were the pools of all deoxyribonucleoside-5"-triphosphates. Nucleosides 69-79 interferon alpha 1 Homo sapiens 14-23 2393279-10 1990 These data suggest that IFN-alpha-induced alterations in nucleoside metabolism may be one mechanism whereby IFN-alpha and acyclovir express synergistic antiherpes-virus activity. Nucleosides 57-67 interferon alpha 1 Homo sapiens 24-33 2393279-10 1990 These data suggest that IFN-alpha-induced alterations in nucleoside metabolism may be one mechanism whereby IFN-alpha and acyclovir express synergistic antiherpes-virus activity. Nucleosides 57-67 interferon alpha 1 Homo sapiens 108-117 28854883-0 2017 Addition of nucleoside analogues to peg-IFNalpha-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNalpha-2a: a randomized controlled trial. Nucleosides 12-22 interferon alpha 1 Homo sapiens 40-48 26845980-0 2015 [Efficacy and safety of pegylated-IFN alpha sequential therapy at stopping nucleotide or nucleoside analogues in patients with hepatitis B under the analogue therapy]. Nucleosides 89-99 interferon alpha 1 Homo sapiens 34-43 28249574-14 2017 CONCLUSIONS: This case-report highlights the risk of HBV reactivation with interferon-free DAA treatment in HIV/HCV co-infected patients previously exposed to HBV and who have contraindications for treatment with nucleoside/nucleotide reverse transcriptase Inhibitors because of comorbid conditions. Nucleosides 213-223 interferon alpha 1 Homo sapiens 75-85 25594111-1 2015 AIM: The factors associated with the outcome of sequential therapy with interferon-alpha (IFN-alpha) in order to halt nucleoside/nucleotide analog (NUC) maintenance treatment for chronic hepatitis B were analyzed. Nucleosides 118-128 interferon alpha 1 Homo sapiens 90-99